SUSAN BLANEY to Macaca mulatta
This is a "connection" page, showing publications SUSAN BLANEY has written about Macaca mulatta.
Connection Strength
1.309
-
Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jun; 53(6):527-32.
Score: 0.204
-
Modified procedure for implantation of subcutaneous central venous access devices in macaques (Macaca mulatta). Comp Med. 2000 Oct; 50(5):486-9.
Score: 0.161
-
Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol. 1998; 41(6):464-8.
Score: 0.133
-
Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates. Cancer Chemother Pharmacol. 2011 Apr; 67(4):809-12.
Score: 0.079
-
Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Cancer Chemother Pharmacol. 2008 Apr; 61(4):647-52.
Score: 0.064
-
Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. Cancer Chemother Pharmacol. 2007 May; 59(6):743-7.
Score: 0.061
-
Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol. 2007 Mar; 59(4):461-6.
Score: 0.060
-
Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin Cancer Res. 2005 Aug 15; 11(16):5981-3.
Score: 0.057
-
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005 Mar 01; 23(7):1555-63.
Score: 0.055
-
Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates. Cancer Chemother Pharmacol. 2004 Aug; 54(2):127-30.
Score: 0.052
-
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res. 2004 Apr 01; 10(7):2525-9.
Score: 0.051
-
Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jul; 54(1):85-8.
Score: 0.051
-
Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jan; 53(1):39-42.
Score: 0.050
-
Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. Cancer Chemother Pharmacol. 1999; 43(5):415-8.
Score: 0.036
-
Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Antimicrob Agents Chemother. 1995 Dec; 39(12):2779-82.
Score: 0.029
-
Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol. 1995; 36(2):121-4.
Score: 0.027
-
Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol. 1995 Jan; 13(1):177-9.
Score: 0.027
-
Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res. 1993 Feb 15; 53(4):725-7.
Score: 0.024
-
Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates. Cancer Res. 1990 Dec 15; 50(24):7915-9.
Score: 0.020
-
Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010 Feb; 65(3):419-25.
Score: 0.018
-
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates. Cancer Chemother Pharmacol. 2009 Jul; 64(2):335-40.
Score: 0.018
-
Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin Cancer Res. 2002 Jul; 8(7):2437-42.
Score: 0.011
-
Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate. Clin Cancer Res. 2000 Mar; 6(3):994-7.
Score: 0.010
-
Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol. 2000; 45(3):259-64.
Score: 0.010